At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study of Galantamine and CBT4CBT to Reduce Post-taper Relapse for MAT
In Brief
A Early Phase 1 clinical trial evaluating MAT taper with galantamine and MAT taper with placebo for Methadone or Buprenorphine Detoxoxification. Completed, enrolled 6 participants across 1 site.
Detailed Summary
The investigators are proposing a randomized pilot feasibility study to evaluate the effects of galantamine versus placebo on preventing relapse to opioid use following tapering from methadone or buprenorphine maintenance (Medication Assisted Treatment, or MAT) among adults with opioid use disorder, with additional behavioral therapy (web-based cognitive behavioral therapy) provided across all conditions to help individuals successfully transition from MAT to a drug-free state.
Study Details
Timeline
Interventions
Following taper from MAT (methadone or buprenorphine) participants will be given galantamine daily with access to a CBT4CBT computer program
Following taper from MAT (methadone or buprenorphine) participants will be given placebo daily with access to a CBT4CBT computer program